Fusion Antibodies
Antibody Discovery and Development Advancing Healthcare.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | £1.2m | Post IPO Equity |
| Total Funding | 000k | ||
| GBP | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 7 % | 15 % | (40 %) | (61 %) | 73 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (11 %) | (13 %) | (12 %) | (86 %) | (182 %) | (71 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (18 %) | (70 %) | (25 %) | (89 %) | (196 %) | (75 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Fusion Antibodies specializes in the development of antibodies for therapeutic drug and diagnostic applications, serving clients in the pharmaceutical and biotechnology sectors. Operating in the global biologics market, the company offers a comprehensive range of services from discovery to clinical supply. Its business model focuses on providing specialized services such as antibody engineering, humanization, and affinity maturation, which are critical for the development of effective therapeutic antibodies. Fusion Antibodies generates revenue by offering these services to companies seeking to develop new antibody-based therapies. The company has extensive experience, having worked on over 150 humanization projects and designed more than 10,000 humanized antibodies. By leveraging its expertise, Fusion Antibodies aims to de-risk projects for its clients, ensuring high-quality outcomes. The company is also involved in various industry events, showcasing its capabilities and expanding its network within the biologics community.
Keywords: antibody, therapeutic, diagnostic, humanization, affinity maturation, pharmaceutical, biotechnology, biologics, clinical supply, engineering